ImmunityBio Inc.

4 days ago · zacks.com

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 days ago · defenseworld.net

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target

19 days ago · zacks.com

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?

19 days ago · seekingalpha.com

ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.

1 month ago · prnewswire.com

Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc. (NASDAQ: CAPR) What: Securities fraud class action lawsuit filed Class Period: December 17, 2025 through July 26, 2026 Deadline to Seek Lead Plaintiff Status: September 28, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead product candidates statistical analysis plan and FDA compliance Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.

1 month ago · defenseworld.net

Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 75,050 shares of the company's stock, valued at approximately $657,000. A number of other large investors have also

1 month ago · defenseworld.net

Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,447,843 shares of the company's stock after purchasing an additional 65,340 shares during the quarter. Bank of

1 month ago · businesswire.com

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leade.

2 months ago · zacks.com

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

2 months ago · zacks.com

ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago.